Diaryltriazine non-nucleoside reverse transcriptase inhibitors are potent candidates for pre-exposure prophylaxis in the prevention of sexual HIV transmission.

OBJECTIVES Pre-exposure prophylaxis and topical microbicides are important strategies in the prevention of sexual HIV transmission, especially since partial protection has been shown in proof-of-concept studies. In search of new candidate drugs with an improved toxicity profile and with activity against common non-nucleoside reverse transcriptase inhibitor (NNRTI)-resistant HIV, we have synthesized and investigated a library of 60 new diaryltriazine analogues. METHODS From this library, 15 compounds were evaluated in depth using a broad armamentarium of in vitro assays that are part of a preclinical testing algorithm for microbicide development. Antiviral activity was assessed in a cell line, and in primary human cells, against both subtype B and subtype C HIV-1 and against viruses resistant to therapeutic NNRTIs and the candidate NNRTI microbicide dapivirine. Toxicity towards primary blood-derived cells, cell lines originating from the female reproductive tract and female genital microflora was also studied. RESULTS AND CONCLUSIONS We identified several compounds with highly potent antiviral activity and toxicity profiles that are superior to that of dapivirine. In particular, compound UAMC01398 is an interesting new candidate that warrants further investigation because of its superior toxicity profile and potent activity against dapivirine-resistant viruses.

[1]  A. Gettie,et al.  The nonnucleoside reverse transcription inhibitor MIV-160 delivered from an intravaginal ring, but not from a carrageenan gel, protects against simian/human immunodeficiency virus-RT Infection. , 2012, AIDS research and human retroviruses.

[2]  Ashley T. Haase,et al.  Targeting early infection to prevent HIV-1 mucosal transmission , 2010, Nature.

[3]  G. Doncel,et al.  Preclinical evaluation of anti-HIV microbicide products: New models and biomarkers. , 2010, Antiviral research.

[4]  D. Phillips,et al.  Carrageenan/MIV-150 (PC-815), a Combination Microbicide , 2007, Sexually transmitted diseases.

[5]  K. Hertogs,et al.  Synthesis of novel diarylpyrimidine analogues of TMC278 and their antiviral activity against HIV-1 wild-type and mutant strains. , 2007, European journal of medicinal chemistry.

[6]  P. Selhorst,et al.  Human Immunodeficiency Virus Type 1 Resistance or Cross-Resistance to Nonnucleoside Reverse Transcriptase Inhibitors Currently under Development as Microbicides , 2011, Antimicrobial Agents and Chemotherapy.

[7]  A. Gettie,et al.  An Antiretroviral/Zinc Combination Gel Provides 24 Hours of Complete Protection against Vaginal SHIV Infection in Macaques , 2011, PloS one.

[8]  Ronald S Veazey,et al.  Partial protection against multiple RT-SHIV162P3 vaginal challenge of rhesus macaques by a silicone elastomer vaginal ring releasing the NNRTI MC1220. , 2013, The Journal of antimicrobial chemotherapy.

[9]  S. Antimisiaris,et al.  Protective properties of non-nucleoside reverse transcriptase inhibitor (MC1220) incorporated into liposome against intravaginal challenge of Rhesus macaques with RT-SHIV. , 2010, Virology.

[10]  S. Kapiga,et al.  Safety, tolerability, and systemic absorption of dapivirine vaginal microbicide gel in healthy, HIV-negative women , 2009, AIDS.

[11]  J. Heeres,et al.  Reverse transcriptase inhibitors as microbicides. , 2012, Current HIV research.

[12]  P. Lewi,et al.  In Vitro Pre- and Post-Exposure Prophylaxis Using HIV Inhibitors as Microbicides Against Cell-Free or Cell-Associated HIV-1 Infection , 2007, Antiviral chemistry & chemotherapy.

[13]  Lieven Baert,et al.  Pharmacokinetics and Disposition of Rilpivirine (TMC278) Nanosuspension as a Long-Acting Injectable Antiretroviral Formulation , 2010, Antimicrobial Agents and Chemotherapy.

[14]  L. van Damme,et al.  Current status of topical antiretroviral chemoprophylaxis , 2012, Current opinion in HIV and AIDS.

[15]  K. Watson,et al.  The Structure-Activity Relationships of 2,4(1H,3H)-pyrimidinedione Derivatives as potent HIV type 1 and type 2 inhibitors , 2007, Antiviral chemistry & chemotherapy.

[16]  S. Antimisiaris,et al.  Topical nonnucleoside reverse transcriptase inhibitor MC 1220 partially prevents vaginal RT-SHIV infection of macaques. , 2011, AIDS research and human retroviruses.

[17]  Sepideh Habibi,et al.  Pharmacokinetics of 2 Dapivirine Vaginal Microbicide Gels and Their Safety Vs. Hydroxyethyl Cellulose-Based Universal Placebo Gel , 2010, Journal of acquired immune deficiency syndromes.

[18]  R. Shattock,et al.  Inhibition of Human Immunodeficiency Virus Type 1 Infection by the Candidate Microbicide Dapivirine, a Nonnucleoside Reverse Transcriptase Inhibitor , 2008, Antimicrobial Agents and Chemotherapy.

[19]  Douglas J. Taylor,et al.  Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in Women: Supporting Online Material , 2010 .

[20]  Brigitte E. Sanders-Beer,et al.  Development of a Comprehensive Human Immunodeficiency Virus Type 1 Screening Algorithm for Discovery and Preclinical Testing of Topical Microbicides , 2008, Antimicrobial Agents and Chemotherapy.

[21]  A. Gettie,et al.  The Nonnucleoside Reverse Transcriptase Inhibitor MIV-150 in Carrageenan Gel Prevents Rectal Transmission of Simian/Human Immunodeficiency Virus Infection in Macaques , 2011, Journal of Virology.

[22]  R. Buckheit,et al.  Development of Dual-Acting Pyrimidinediones as Novel and Highly Potent Topical Anti-HIV Microbicides , 2011, Antimicrobial Agents and Chemotherapy.

[23]  Jan Balzarini,et al.  In Vitro Evaluation of Nonnucleoside Reverse Transcriptase Inhibitors UC-781 and TMC120-R147681 as Human Immunodeficiency Virus Microbicides , 2004, Antimicrobial Agents and Chemotherapy.

[24]  G. Vanham,et al.  HIV sexual transmission and microbicides , 2011, Reviews in medical virology.

[25]  M. Wainberg,et al.  Antiviral Drug Resistance and the Need for Development of New HIV-1 Reverse Transcriptase Inhibitors , 2012, Antimicrobial Agents and Chemotherapy.

[26]  G. Vanham,et al.  Searching for Lower Female Genital Tract Soluble and Cellular Biomarkers: Defining Levels and Predictors in a Cohort of Healthy Caucasian Women , 2012, PloS one.

[27]  J. Nuttall,et al.  Concentrations of Dapivirine in the Rhesus Macaque and Rabbit following Once Daily Intravaginal Administration of a Gel Formulation of [14C]Dapivirine for 7 Days , 2007, Antimicrobial Agents and Chemotherapy.

[28]  M. Wainberg,et al.  Synergy against drug-resistant HIV-1 with the microbicide antiretrovirals, dapivirine and tenofovir, in combination , 2011, AIDS.

[29]  A. Gettie,et al.  A single dose of a MIV-150/Zinc acetate gel provides 24 h of protection against vaginal simian human immunodeficiency virus reverse transcriptase infection, with more limited protection rectally 8-24 h after gel use. , 2012, AIDS research and human retroviruses.

[30]  C. Dezzutti,et al.  Characterization of UC781-Tenofovir Combination Gel Products for HIV-1 Infection Prevention in an Ex Vivo Ectocervical Model , 2012, Antimicrobial Agents and Chemotherapy.

[31]  J. Grivel,et al.  Ex vivo culture of human colorectal tissue for the evaluation of candidate microbicides , 2006, AIDS.

[32]  A. Gettie,et al.  Efficacy of Carraguard®-Based Microbicides In Vivo Despite Variable In Vitro Activity , 2008, PloS one.

[33]  J. Mcnicholl,et al.  Safe and Sustained Vaginal Delivery of Pyrimidinedione HIV-1 Inhibitors from Polyurethane Intravaginal Rings , 2011, Antimicrobial Agents and Chemotherapy.

[34]  A. Nel,et al.  Pharmacokinetic assessment of dapivirine vaginal microbicide gel in healthy, HIV-negative women. , 2010, AIDS research and human retroviruses.

[35]  P. Lewi,et al.  A Series of Diaryltriazines and Diarylpyrimidines Are Highly Potent Nonnucleoside Reverse Transcriptase Inhibitors with Possible Applications as Microbicides , 2004, Antimicrobial Agents and Chemotherapy.

[36]  G. Vanham,et al.  Development of an in vitro dual-chamber model of the female genital tract as a screening tool for epithelial toxicity. , 2010, Journal of virological methods.

[37]  C. Mowbray.  Pyrazole NNRTIs 4: Selection of UK‐453,061 (Lersivirine) as a Development Candidate. , 2010 .

[38]  A. Buvé,et al.  Dose-Ranging Phase 1 Study of TMC120, a Promising Vaginal Microbicide, in HIV-Negative and HIV-Positive Female Volunteers , 2007, Journal of acquired immune deficiency syndromes.

[39]  G. Shaw,et al.  HIV transmission. , 2012, Cold Spring Harbor perspectives in medicine.

[40]  F. Belardelli,et al.  Inhibition of vaginal transmission of HIV-1 in hu-SCID mice by the non-nucleoside reverse transcriptase inhibitor TMC120 in a gel formulation , 2003, AIDS.

[41]  A. Gettie,et al.  An Intravaginal Ring That Releases the NNRTI MIV-150 Reduces SHIV Transmission in Macaques , 2012, Science Translational Medicine.

[42]  R. Pauwels,et al.  Evolution of anti-HIV drug candidates. Part 2: Diaryltriazine (DATA) analogues. , 2001, Bioorganic & medicinal chemistry letters.

[43]  R. Buckheit,et al.  An algorithm for the preclinical development of anti-HIV topical microbicides. , 2012, Current HIV research.

[44]  John P. Moore,et al.  Escape of HIV-1 from a Small Molecule CCR5 Inhibitor Is Not Associated with a Fitness Loss , 2007, PLoS pathogens.